【學(xué)術(shù)報(bào)告】Cancer Theranostics/腫瘤原位納米疫苗/Lu-177/Ac-225-Based Radiotheranostics
日期：2023-05-18
閱讀：3621
學(xué)術(shù)報(bào)告一
題目：Cancer Theranostics
報(bào)告人：陳小元博士，新加坡國立大學(xué)醫(yī)學(xué)院和工程學(xué)院終身講席教授
時(shí)間：2023年5月18日 下午15：00
地點(diǎn)：霞光樓200號(hào)
邀請(qǐng)人：周永豐 教授
報(bào)告摘要：
Theranostics, the combination of ther(apy) and (diag)nostics, aims to develop molecular diagnostic tests and targeted therapeutics with the goals of individualizing treatment by targeting therapy to an individual's specific disease subtype and genetic profile. It can be diagnosis followed by therapy to stratify patients who will likely respond to a given treatment. It can also be therapy followed by diagnosis to monitor early response to treatment and predict treatment efficacy. It is also possible that diagnostics and therapeutics are co-developed (sonotheranostics, immunotheranostics, magnetotheranostics, optotheranostics, radiotheranostics, etc.). This talk will highlight two representative types of theranostics, namely radiotheranostics and immunotheranostics, in cancer imaging and therapy. Some translational work will also be mentioned.
學(xué)術(shù)報(bào)告二
題目：腫瘤原位納米疫苗
報(bào)告人：鄧宏章博士，西安電子科技大學(xué)教授
時(shí)間：2023年5月18日 下午16：00
地點(diǎn)：霞光樓200號(hào)
邀請(qǐng)人：周永豐 教授
報(bào)告摘要：
在所有威脅人類健康的疾病中，癌癥無疑已經(jīng)躍居榜首。傳統(tǒng)治療方式下腫瘤細(xì)胞凋亡之后的碎片可以作為抗原來激活腫瘤原位樹突狀細(xì)胞，進(jìn)而引出免疫響應(yīng)來實(shí)現(xiàn)腫瘤治療。然后，由于腫瘤自身復(fù)雜的微環(huán)境以及保護(hù)機(jī)制，免疫性凋亡所產(chǎn)生的免疫響應(yīng)比較微弱，并不能實(shí)現(xiàn)腫瘤治療的目的。為此，結(jié)合先進(jìn)納米材料策略，以復(fù)雜腫瘤微環(huán)境為突破口來增強(qiáng)傳統(tǒng)治療方式所引發(fā)的免疫性凋亡是解決上述科學(xué)問題有效途徑。構(gòu)建多功能高分子原位納米疫苗遞送系統(tǒng)來重塑腫瘤細(xì)胞凋亡之后的抗原性與佐劑性，實(shí)現(xiàn)高效的腫瘤抑制。
學(xué)術(shù)報(bào)告三
題目：Lu-177/Ac-225-Based Radiotheranostics
報(bào)告人：張靜靜博士，新加坡國立大學(xué)
時(shí)間：2023年5月18日 下午16：30
地點(diǎn)：霞光樓200號(hào)
邀請(qǐng)人：周永豐 教授
報(bào)告摘要：
Radionuclide theranostics for precision oncology is being driven by rapid advances in novel diagnostics and therapeutic interventions, with dramatically expanded radiopharmaceuticals toolbox over the last few years. The rapid development and availability of new isotopes and agents has fundamentally changed the landscape for molecular targeted therapy. 177Lu-PRRT lends a significant benefit in progression free survival as well as in overall survival in metastasized and/or progressive NENs as compared to other treatment modalities and regardless of previous therapies. 177Lu-PSMA RLT is safe and effective with appropriate selection and follow-up of patients by 68Ga-PSMA PET/CT applying the concept of theranostics. The initial clinical results of PTRT provide preliminary evidence for the feasibility of radiomolecular precision theranostics using the novel FAP targeted radiolabeled ligands as well as TANDEM 177Lu-/225Ac- and 90Y-/225Ac-FAP of a number of advanced, therapy-refractory adenocarcinomas. Specific uptake and long tumor retention of the radioligands ensure usability of therapeutically effective longer-lived radionuclides for therapy. New strategies and platforms including new targets, novel radionuclides such as alpha emitter (225Ac, 212Pb), tumor microenvironment with optimized ligands and optimal isotopes (177Lu, 225Ac, 90Y, TANDEM) and administration schedules will be systematically explored in the near future.
